Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
3
users have commented on this narrative
45
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Medical Properties Trust
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Eroding Hospital Demand And Tight Credit Will Hurt Rental Income
Key Takeaways Shifting healthcare delivery models and regulatory challenges threaten demand for hospital real estate and undermine stability of rental income and earnings. Elevated debt costs, tenant financial strain, and ongoing asset sales further weaken growth prospects and increase risks to cash flow and asset values.
View narrative
US$3.50
FV
15.7% overvalued
intrinsic discount
3.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Mercury Systems
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Government Deficits And Rising Input Costs Will Squeeze Margins
Key Takeaways Defense budget pressures and shifting market demand threaten revenue growth and squeeze gross margins, especially as elevated costs pass through the supply chain. Intensifying competition and rapid technological change require costly innovation, risking lower earnings visibility and diminished returns if product relevance fades.
View narrative
US$39.57
FV
68.5% overvalued
intrinsic discount
4.17%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
1 day ago
author updated this narrative
Recursion Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
High R&D Burn And Regulatory Hurdles Will Cripple Future Value
Key Takeaways High R&D spending and lack of commercial assets expose the company to negative cash flow, dilution, and earnings risk. Regulatory uncertainty, revenue instability from partnerships, and increasing competition jeopardize growth, margins, and long-term market potential.
View narrative
US$3.00
FV
92.3% overvalued
intrinsic discount
11.22%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Alignment Healthcare
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Rising CMS Pressures And Margin Risks Will Drag Performance
Key Takeaways Exposure to regulatory changes, margin pressures, and rising costs threatens profitability and long-term stability in a competitive, evolving Medicare Advantage market. Persistent negative cash flow, thin margins, and potential reliance on outside financing undermine sustainable growth as operational and audit risks intensify.
View narrative
US$13.28
FV
13.3% overvalued
intrinsic discount
25.61%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
QuidelOrtho
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Debt And Costs Will Squeeze Margins As Markets Rebound
Key Takeaways Cost pressures and shifting reimbursement trends threaten long-term revenue growth and margin expansion, despite rising global demand for advanced diagnostics and planned operational improvements. Expansion into underpenetrated and emerging markets is challenged by government price controls and aggressive local competition, constraining sustainable revenue and margin gains.
View narrative
US$26.00
FV
0.3% undervalued
intrinsic discount
2.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
NovoCure
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Regulatory Delays And Setbacks Will Restrict Adoption Yet Allow Recovery
Key Takeaways Heavy reliance on Tumor Treating Fields exposes the company to revenue risks amid slow reimbursement and potential advances in competing therapies. High research and development costs, extended clinical timelines, and regulatory barriers could delay profitability and limit near-term market expansion.
View narrative
US$14.50
FV
19.1% undervalued
intrinsic discount
6.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Twist Bioscience
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
DNA Synthesis Commoditization And Trade Tensions Will Erode Margins
Key Takeaways Intensifying competition and industry consolidation are driving down margins, pressuring Twist Bioscience to increase spending on innovation and commercialization. Heavy reliance on a few customers heightens revenue volatility, while operational costs and regulatory risks challenge the path to consistent profitability.
View narrative
US$25.00
FV
12.5% overvalued
intrinsic discount
15.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
PAR Technology
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Rising Cybersecurity And Integration Risks Will Limit Future Gains
Key Takeaways Rising cybersecurity, regulatory, and integration challenges threaten PAR Technology's margins, operational efficiency, and the realization of scalable SaaS profitability. Heavy reliance on a few major clients and intensifying competition may result in volatile revenues, market share losses, and diminished pricing power.
View narrative
US$50.00
FV
3.9% overvalued
intrinsic discount
13.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
LifeStance Health Group
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Digital Advances Will Strain Mental Health Care Yet Recovery Awaits
Key Takeaways Increased competition from digital and integrated health providers, alongside clinician turnover, threatens growth in patient volume, market share, and margins. Regulatory changes and costly technology investments may slow expansion and limit profitability, despite growing mental health awareness and insurance coverage.
View narrative
US$6.50
FV
16.3% undervalued
intrinsic discount
14.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Value any company in seconds
Popular companies